Update shared on 14 Nov 2025
Fair value Increased 0.33%Narrative Update: Labcorp Holdings Analyst Price Target Adjustment
Analysts have raised their price target for Labcorp Holdings by $1. This change reflects a marginally improved outlook based on updated fair value and company fundamentals.
What's in the News
- Labcorp updated its financial guidance for full year 2025, lowering expected revenue growth to a range of 7.4% to 8.0%. This compares to the previous range of 7.5% to 8.6% (Key Developments).
- The company recently completed another tranche of its share buyback program. Labcorp repurchased 100,000 shares for $27.71 million, bringing total shares repurchased to over 14.3 million since December 2021 (Key Developments).
- Labcorp announced plans to offer the Elecsys pTau181 test, the only FDA-cleared blood test to aid primary-care assessment of Alzheimer's disease, nationwide by early 2026 (Key Developments).
- A successful collaboration with Praia Health at Providence improved lab appointment adherence, patient engagement, and operational efficiency. This included an eightfold increase in scheduled appointments (Key Developments).
- Labcorp launched the Lumipulse pTau-217/Beta Amyloid 42 Ratio test, the first FDA-cleared blood-based IVD for Alzheimer's diagnosis, now available nationwide (Key Developments).
Valuation Changes
- Fair Value has risen slightly, from $299.12 to $300.12.
- Discount Rate increased modestly, moving from 6.78% to 6.96%.
- Revenue Growth projection has edged down, from 4.80% to 4.78%.
- Net Profit Margin improved marginally, rising from 8.72% to 8.73%.
- Future P/E decreased slightly, from 21.34x to 21.24x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.